Intravenous administration of norepinephrine in a patient already taking an effective dose of atropine will often:
**Core Concept**
The interaction between norepinephrine and atropine is a classic pharmacological principle in critical care medicine. Norepinephrine is a potent alpha-1 adrenergic agonist that increases blood pressure by causing vasoconstriction, while atropine is an anticholinergic agent that blocks the action of acetylcholine at muscarinic receptors, thereby increasing heart rate.
**Why the Correct Answer is Right**
When norepinephrine is administered intravenously in a patient already taking an effective dose of atropine, the primary effect is an increase in blood pressure due to vasoconstriction. However, the co-administration of atropine can lead to a reflex bradycardia, as the blockade of muscarinic receptors reduces the negative feedback inhibition of the sympathetic nervous system. This can result in a paradoxical decrease in heart rate despite the administration of a potent vasoconstrictor like norepinephrine.
**Why Each Wrong Option is Incorrect**
**Option A:** This is not a correct description of the interaction between norepinephrine and atropine. The administration of norepinephrine does not cause a decrease in heart rate.
**Option B:** This option is also incorrect, as the administration of norepinephrine does not cause a significant increase in cardiac output in the presence of atropine.
**Option C:** This option is incorrect, as the administration of norepinephrine does not cause a significant decrease in systemic vascular resistance in the presence of atropine.
**Clinical Pearl / High-Yield Fact**
When administering norepinephrine in a patient already taking atropine, it is essential to monitor the patient's heart rate closely, as reflex bradycardia can occur. This can be mitigated by co-administering a beta-2 agonist like isoproterenol to increase heart rate.
**Correct Answer: C. The blood pressure may increase, but the heart rate may decrease due to reflex bradycardia caused by the blockade of muscarinic receptors by atropine.**